{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T06:07:05Z","timestamp":1749103625496,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T00:00:00Z","timestamp":1703894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T00:00:00Z","timestamp":1703894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Gastroenterol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s12664-023-01480-3","type":"journal-article","created":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T04:33:20Z","timestamp":1703910800000},"page":"652-659","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-term entecavir therapy of chronic hepatitis B in real-life setting\u2014Importance of quantitative HBsAg level"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4859-8729","authenticated-orcid":false,"given":"Gautam","family":"Ray","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,30]]},"reference":[{"unstructured":"Hepatitis B [https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis B]. Accessed 14\/07\/2023.","key":"1480_CR1"},{"unstructured":"World Health Organization (WHO).\u00a0Global hepatitis report. 2017;2017: 83.","key":"1480_CR2"},{"key":"1480_CR3","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.3390\/ijms22031456","volume":"22","author":"K Yoshida","year":"2021","unstructured":"Yoshida K, Enomoto M, Tamori A, Nishiguchi S, Kawada N. Combination of entecavir or tenofovir with pegylated interferon-\u03b1 for long-term reduction in hepatitis B surface antigen levels: simultaneous, sequential, or add-on combination therapy. Int J Mol Sci. 2021;22:1456.","journal-title":"Int J Mol Sci"},{"key":"1480_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/liv.13291","volume":"37 Suppl. 1","author":"G Grossi","year":"2017","unstructured":"Grossi G, Vigan\u00f2 M, Loglio A, Lampertico P. Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs). Liver Int. 2017;37 Suppl. 1:45\u201351.","journal-title":"Liver Int"},{"key":"1480_CR5","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3390\/v14020434","volume":"14","author":"RN Chien","year":"2022","unstructured":"Chien RN, Liaw YF. Current trend in antiviral therapy for chronic hepatitis B. Viruses. 2022;14:434.","journal-title":"Viruses"},{"key":"1480_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/HMER.S291976","volume":"14","author":"T Broquetas","year":"2022","unstructured":"Broquetas T, Carri\u00f3n JA. Current perspectives on nucleos(t)ide analogue therapy for the long-term treatment of hepatitis B virus. Hepat Med. 2022;14:87\u2013100.","journal-title":"Hepat Med"},{"key":"1480_CR7","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cgh.2019.07.010","volume":"18","author":"JL Hou","year":"2020","unstructured":"Hou JL, Zhao W, Lee C, et al. Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries. Clin Gastroenterol Hepatol. 2020;18:457\u201367.e21.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1480_CR8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s00535-018-1502-y","volume":"54","author":"F Suzuki","year":"2019","unstructured":"Suzuki F, Hosaka T, Suzuki Y, et al. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-na\u00efve chronic hepatitis B patients in Japan. J Gastroenterol. 2019;54:182\u201393.","journal-title":"J Gastroenterol"},{"key":"1480_CR9","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3904\/kjim.2016.096","volume":"32","author":"JY Cho","year":"2017","unstructured":"Cho JY, Sohn W, Sinn DH, et al. Long-term real-world entecavir therapy in treatment-na\u00efve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response. Korean J Intern Med. 2017;32:636\u201346.","journal-title":"Korean J Intern Med"},{"key":"1480_CR10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.23736\/S1121-421X.18.02470-4","volume":"64","author":"A Collo","year":"2018","unstructured":"Collo A, Belci P, Fagoonee S, et al. Efficacy and safety of long-term entecavir therapy in a European population. Minerva Gastroenterol Dietol. 2018;64:201\u20137.","journal-title":"Minerva Gastroenterol Dietol"},{"key":"1480_CR11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12885-022-09413-7","volume":"22","author":"ZH Huang","year":"2022","unstructured":"Huang ZH, Lu GY, Qiu LX, et al. Risk of hepatocellular carcinoma in antiviral treatment-na\u00efve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis. BMC Cancer. 2022;22:287.","journal-title":"BMC Cancer"},{"key":"1480_CR12","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s12664-015-0576-1","volume":"34","author":"SK Goyal","year":"2015","unstructured":"Goyal SK, Dixit VK, Shukla SK, et al. Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis. Indian J Gastroenterol. 2015;34:286\u201391.","journal-title":"Indian J Gastroenterol"},{"key":"1480_CR13","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jhep.2013.08.023","volume":"60","author":"G Papatheodoridis","year":"2014","unstructured":"Papatheodoridis G, Goulis J, Manolakopoulos S, et al. Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy. J Hepatol. 2014;60:62\u20138.","journal-title":"J Hepatol"},{"key":"1480_CR14","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1038\/ctg.2017.51","volume":"8","author":"YF Lam","year":"2017","unstructured":"Lam YF, Seto WK, Wong D, et al. Seven-year treatment outcome of entecavir in a real-world cohort: effects on clinical parameters, HBsAg and HBcrAg levels. Clin Transl Gastroenterol. 2017;8:e125.","journal-title":"Clin Transl Gastroenterol"},{"key":"1480_CR15","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","volume":"162","author":"G Hirode","year":"2022","unstructured":"Hirode G, Choi HSJ, Chen CH, et al. Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B Study). Gastroenterology. 2022;162:757\u201371.e4.","journal-title":"Gastroenterology"},{"key":"1480_CR16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/jgh.15678","volume":"37","author":"YE Chon","year":"2022","unstructured":"Chon YE, Kim SU, Seo YS, et al. Long-term effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2022;37:200\u20137.","journal-title":"J Gastroenterol Hepatol"},{"key":"1480_CR17","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/hep.26041","volume":"57","author":"TC Tseng","year":"2013","unstructured":"Tseng TC, Liu CJ, Yang HC, et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology. 2013;57:441\u201350.","journal-title":"Hepatology"},{"key":"1480_CR18","doi-asserted-by":"publisher","first-page":"100112","DOI":"10.1016\/j.jhepr.2020.100112","volume":"2","author":"CL Lai","year":"2020","unstructured":"Lai CL, Wong DK, Wong GT, Seto WK, Fung J, Yuen MF. Rebound of HBV DNA after cessation of nucleos\/tide analogues in chronic hepatitis B patients with undetectable covalently closed circular DNA. JHEP Rep. 2020;2:100112.","journal-title":"JHEP Rep."},{"key":"1480_CR19","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1111\/jgh.13377","volume":"31","author":"H Chi","year":"2016","unstructured":"Chi H, Arends P, Reijnders JG, et al. VIRGIL Surveillance Study Group (European Surveillance Network for Vigilance Against Viral Resistance). Flares during long-term entecavir therapy in chronic hepatitis B. J Gastroenterol Hepatol. 2016;31:1882\u20137.","journal-title":"J Gastroenterol Hepatol."},{"key":"1480_CR20","first-page":"277","volume":"5","author":"G Ray","year":"2017","unstructured":"Ray G. Current scenario of hepatitis B and its treatment in India. J Clin Transl Hepatol. 2017;5:277\u201396.","journal-title":"J Clin Transl Hepatol"},{"key":"1480_CR21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s12664-016-0664-x","volume":"35","author":"G Ray","year":"2016","unstructured":"Ray G. 5-year efficacy of entecavir in Indian patients with chronic hepatitis B. Indian J Gastroenterol. 2016;35:190\u20134.","journal-title":"Indian J Gastroenterol"}],"container-title":["Indian Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-023-01480-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12664-023-01480-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-023-01480-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T13:30:48Z","timestamp":1720013448000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12664-023-01480-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,30]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1480"],"URL":"https:\/\/doi.org\/10.1007\/s12664-023-01480-3","relation":{},"ISSN":["0254-8860","0975-0711"],"issn-type":[{"type":"print","value":"0254-8860"},{"type":"electronic","value":"0975-0711"}],"subject":[],"published":{"date-parts":[[2023,12,30]]},"assertion":[{"value":"7 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GR declares no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was performed conforming to the Helsinki Declaration of 1975, as revised in 2000 and 2008 concerning human and animal rights, and the authors followed the policy concerning informed consent as shown on Springer.com.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"Ethics approval and consent to participate and for publication were taken.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, consent to participate, and consent for publication"}},{"value":"The author is solely responsible for the data and the contents of the paper. In no way, the Honorary Editor-in-Chief, Editorial Board Members, the Indian Society of Gastroenterology\u00a0or the printer\/publishers are responsible for the results\/findings and content of this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}